Fact Sheet
Japan Regulatory Circumstance for Clinical Trials
Dec 21, 2021
Download
Japan has implemented a number of initiatives over the last decade to speed approval of new innovative drugs, biologics, and devices that have demonstrated value over existing therapies. As a result, Japan is now 2nd fastest for NDA approval time amongst all major regulatory agencies. This one pager explains the details of Japan regulatory circumstance. IQVIA's experienced regulatory expertise can bring your asset successfully from molecule to market.
Contact Us